- Collaboration leads to major deals in Asia - Annual revenue to reach $60 M for ProMetic in product sales and royalties - Sartorius Stedim Biotech expects significant demand for its products and
AUBAGNE, France, GOETTINGEN, Germany and MONTREAL, Canada, March 18 /PRNewswire-FirstCall/ - Sartorius Stedim Biotech and ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI) announced today the second successful technology transfer deal resulting from their collaboration entered into in 2006. The collaboration positions Sartorius Stedim Biotech as the preferred supplier and technology provider of filtration equipment and consumables to plasma fractionators that have in-licensed ProMetic's proprietary manufacturing process.
ProMetic recently announced that they have signed a strategic alliance and license agreement with the Wuhan Institute of Biological Products ("WIBP"). Under the terms of this agreement, WIBP gains exclusive access to ProMetic's yield improving plasma protein process for the Chinese market. In addition ProMetic has announced agreements with the Taiwanese biotechnology company Blue-Blood Biotech Corporation ("Blue Blood") for the development and commercialization of human plasma-derived specialty immunoglobulin preparations for the treatment of several infectious diseases including Cytomegalovirus and Enterovirus. Under this agreement, ProMetic would also retain the rights to the hyperimmune products for the North American market.
"These agreements and our relationship with Sartorius Stedim Biotech
contribute to our short term revenue growth and to making our Protein
Technologies business EBITDA positive in 2008 and generating an EBITDA of
$15 to $20 Million in 2009," stated Mr. Pierre Laurin, President and Chief
Executive Officer of ProMetic. "Collectively, these agreements have firmly
established ProMetic's technology in Asia and provide an opportunity to
generate an esti
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved